Validation of the clinical performance and reproducibility of the NeuMoDx HPV assay self-sample workflow

D A M Heideman, J Berkhof, L Verhoef, C Ouwerkerk, P W Smit, A Oštrbenk Valenčak, J Mlakar, M Poljak, R D M Steenbergen, M C G Bleeker

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Human papillomavirus (HPV) testing on self-samples is a valid tool for cervical cancer screening. HPV self-sample workflows need to be clinically validated to ensure safe use in screening. Objective: This study evaluated the fully automated NeuMoDx HPV Assay self-sample workflow that is compiled of the NeuMoDx HPV assay and the NeuMoDx 96/288 Molecular Systems, for clinical performance and reproducibility on Evalyn Brush-collected self-samples. Methods: The clinical performance of the NeuMoDx HPV Assay self-sample workflow for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and CIN3+ was evaluated on 987 self-samples obtained from women attending national organized HPV-based cervical cancer screening by a noninferiority analysis relative to reference workflows using either HPV-Risk Assay or high-risk HPV GP5+/6+-PCR. Intra- and inter-laboratory reproducibility of the NeuMoDx HPV Assay self-sample workflow using both NeuMoDx 96 and 288 Molecular Systems was assessed on 520 self-samples in three laboratories. Results: The clinical sensitivity and specificity of the NeuMoDx HPV Assay self-sample workflow for the detection of CIN2+ and CIN3+ were found to be non-inferior to the reference workflows using either HPV-Risk Assay or high-risk HPV GP5+/6+-PCR, with all p-values <0.034. The NeuMoDx HPV Assay self-sample workflow exhibited an intra-laboratory reproducibility of 94.4 % (95 %CI:92.5–96.1 %) with kappa value 0.86 (95 %CI:0.81–0.91). Inter-laboratory agreement was high (all ≥93.4 % and all kappa values ≥0.83). Conclusions: The NeuMoDx HPV Assay self-sample workflow demonstrated high clinical accuracy for CIN2+/3+ and high reproducibility. The NeuMoDx HPV Assay self-sample workflow can be considered suitable for cervical cancer screening purposes.

Original languageEnglish
Article number105649
Pages (from-to)105649
JournalJournal of clinical virology
Volume171
Early online date1 Feb 2024
DOIs
Publication statusPublished - Apr 2024

Keywords

  • Cervical cancer screening
  • Diagnostic test accuracy
  • HPV
  • NeuMoDx HPV assay
  • Reproducibility
  • Self-sampling

Cite this